Identification of glycosaminoglycan-binding sites within hepatitis C virus envelope glycoprotein E2

Journal of Viral Hepatitis

Volumn 12, Issue 6, 2005, Pages 584-593

  Olenina, Ludmila V ^a   Kuzmina, T I ^a   Sobolev, B N ^a   Kuraeva, T E ^a   Kolesanova, E F ^a   Archakov, A I ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Envelope glycoproteins; Heparin binding sites; Hepatitis C virus

Indexed keywords

DEXTRAN SULFATE; GLYCOPROTEIN E2; GLYCOSAMINOGLYCAN; HEPARAN; HEPARAN SULFATE; HEPARIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

AMINO ACID SEQUENCE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CELL SURFACE; CONFERENCE PAPER; GENETIC CONSERVATION; HEPATITIS C; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN MOTIF; VIRUS ENVELOPE;

AMINO ACID SEQUENCE; BINDING SITES; CONSENSUS SEQUENCE; GLYCOSAMINOGLYCANS; HEPACIVIRUS; HEPARIN; MOLECULAR SEQUENCE DATA; PEPTIDES; VIRAL ENVELOPE PROTEINS;

EID: 27444438668     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00647.x     Document Type: Conference Paper

References (56)

1. Shukla DD, Hoyne PA, Ward CW. Evaluation of complete genome sequences and sequences of individual gene products for the classification of hepatitis C viruses. Arch Virol 1995; 140: 1747-1761.
2. Choo QL, Richman KH, Hart JH et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991; 88: 2451-2457.
3. Clarke B. Molecular virology of hepatitis C virus. J Gen Virol 1997; 78: 2397-2410.
4. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, VandePol S. Rapid evolution of RNA genomes. Science 1982; 215: 1577-1585.
5. Kato N, Ootsuyama Y, Tanaka T et al. Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res 1992; 22: 107-123.
6. Vizmanos JL, Gonzalez-Navarro CJ, Novo FJ et al. Degree and distribution of variability in the 5′ untranslated, E1, E2J NS1 and NS5 regions of the hepatitis C virus (HCV). J Viral Hepat 1998; 5: 227-240.
7. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Ohkoshi S, Shimotohno K. Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Com 1991; 175: 220-228.
8. Martell M, Esteban JI, Quer J et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225-3229.
9. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 1994; 75: 1361-1369.
10. Pileri P, Uematsu Y, Campagnoli S et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-941.
11. Agnello V, Abel G, Elfand M, Knignt GB, Zhang Q-X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-12771.
12. Germi R, Crance JM, Garin D et al. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 2002; 68: 206-215.
13. Scarselli E, Ansuini H, Cerino R et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017-5025.
14. Pohlmann S, Zhang J, Baribaud F et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 2003; 77: 4070-4080.
15. Gardner JP, Durso RJ, Arrigale RR et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci USA 2003; 100: 4498-4503.
16. Lozach PY, Lortat-Jacob H, de Lacroix de Lavalette A et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 2003; 278: 20358-20366.
17. Saunier B, Triyatni M, Ulianich L, Maruvada P, Yen P, Kohn LD. Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J Virol 2003; 77: 546-559.
18. Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 2001; 11: 75-82.
19. Cribier B, Schmitt C, Kirn A, Stoll-Keller F. Inhibition of hepatitis C virus adsorption to peripheral blood mononuclear cells by dextran sulfate. Arch Virol 1998; 143: 375-379.
20. Garson JA, Lubach D, Passas J, Whitby K, Grant PR. Suramin blocks hepatitis C binding to human hepatoma cells in vitro. J Med Virol 1999; 57: 238-242.
21. Meyer K, Basu A, Ray R. Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells. Virology 2000; 276: 214-226.
22. Barth H, Schafer C, Adah MI et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003; 278: 41003-41012.
23. Yagnik AT, Lahm A, Meola A et al. A model for the hepatitis C virus envelope glycoprotein E2. Proteins 2000; 40: 355-366.
24. Caldwell EE, Nadkarni VD, Fromm JR, Linhardt RJ, Weiler JM. Importance of specific amino acids in protein binding sites for heparin and heparan sulfate. Int J Biochem Cell Biol 1996; 28: 203-216.
25. Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989; 9: 21-32.
26. Sobel M, Soler DF, Kermode JC, Harris RB. Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. J Biol Chem 1992; 267: 8857-8862.
27. Margalit H, Fischer N, Ben Sasson SA. Comparative analysis of structurally defined heparin binding sequences reveals a distinct spatial distribution of basic residues. J Biol Chem 1993; 268: 19228-19231.
28. Sobolev BN, Poroikov VV, Olenina LV, Kolesanova EF, Archakov AI. Comparative analysis of amino acid sequences from envelope proteins isolated from different hepatitis C virus variants: possible role of conservative and variable regions. J Viral Hepatitis 2000; 7: 368-374.
29. Sobolev BN, Poroikov VV, Olenina LV, Kolesanova EF, Archakov AI. Analysis of hepatitis C virus proteins on the basis of amino acid sequences and literature data. Biofizika 2002; 47: 204-210.
30. Falquet L, Pagni M, Bucher P et al. The PROSITE database, its status in 2002. Nucleic Acids Res 2002; 30: 235-238.
31. Rodda SJ, Tribbick G. Antibody-defined epitope mapping using the multipin method of peptide synthesis. Methods 1996; 9: 473-481.
32. Drake SL, Varnum J, Mayo KH, Letourneau PC, Furcht LT, McCarthy JB. Structural features of fibronectin synthetic peptide FN-C/H II, responsible for cell adhesion, neurite extension, and heparan sulfate binding. J Biol Chem 1993; 268: 15859-15867.
33. Cardin AD, Hirose N, Blankenship DT et al. Binding of high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. Biochem Biophys Res Com 1986; 134: 783-789.
34. Lawler J, Duquette M, Ferro P. Cloning and sequencing of chicken trombospondin. J Biol Chem 1991; 266: 8039-8043.
35. 2+ channels. J Biol Chem 1990; 265: 11156-11166.
36. Shukla D, Spear PG. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J Clin Invest 2001; 108: 503-510.
37. Deng H, Liu R, Ellmeier W. Identification of a major co-receptor for primary isolates of HIV. Nature 1996; 381: 661-664.
38. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280: 1884-1888.
39. Akula SM, Wang FZ, Vieira J, Chandran B. Human herpesvirus 8 interaction with target cells involves heparan sulfate. Virology 2001; 282: 245-255.
40. Moulard M, Lortat-Jacob H, Mondor I et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000; 74: 1948-1960.
41. Martinez I, Melero JA. Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. J Gen Virol 2000; 81(Pt 11): 2715-2722.
42. Geuijen CA, Willems RJ, Hoogerhout P, Puijk WC, Meloen RH, Mooi FR. Identification and characterization of heparin binding regions of the Fim2 subunit of Bordetella pertussis. Infect Immun 1998; 66: 2256-2263.
43. Pinzon-Ortiz C, Friedman J, Esko J, Sinnis P. The binding of the circumsporozoite protein to cell surface heparan sulfate proteoglycans is required for plasmodium sporozoite attachment to target cells. J Biol Chem 2001; 276: 26784-26791.
44. Chen Y, Maguire T, Hileman RE et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 1997; 3: 866-871.
45. Hilgard P, Stockert R. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology 2000; 32: 1069-1077.
46. Takikawa S, Ishii K, Aizaki H, Abrignani S, Matsuura Y, Miyamura T. Cell fusion activity of hepatitis C virus envelope proteins. J Virol 2000; 74: 5066-5074.
47. Basy A, Beyene A, Meyer K, Ray R. The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system. J Virol 2004; 78: 4478-4486.
48. Flint M, Maidens C, Loomis-Price LD et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 1999; 73: 6235-6244.
49. Roccasecca R, Ansuini H, Vitelli A et al. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol 2003; 77: 1856-1867.
50. Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH. Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 2001; 82: 1877-1883.
51. Olenina LV, Nikolaeva LI, Sobolev BN, Blokhina NP, Archakov AI, Kolesanova EF. Mapping and characterization of B cell linear epitopes in the conservative regions of hepatitis C virus envelope glycoproteins. J Viral Hepat 2002; 9: 174-182.
52. Zhang ZX, Sonnerborg A, Sallberg M. Antigenic structure of the hepatitis C virus envelope 2 protein. Clin Exp Immunol 1994; 98: 382-387.
53. Zibert A, Kraas W, Ross RS et al. Immunodominant B-cell domains of hepatitis C virus envelope proteins E1 and E2 identified during early and late time points of infection. J Hepatol 1999; 30: 177-184.
54. Clayton RF, Owsianka A, Aitken J, Graham S, Bhella D, Patel AH, Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol 2002; 76: 7672-7682.
55. Bartoch B, Vitelli A, Granier Ch et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003; 278: 41624-41630.
56. Lyon M, Deakin JA, Gallagher JT. Liver heparan sulfate structure. A novel molecular design. J Biol Chem 1994; 269: 11208-11215.